Loading…
Viral Hepatitis Testing Act of 2015
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 3,548 other S bills in the 114th — cohort avg 43d
Viral Hepatitis Testing Act of 2015 Amends the Public Health Service Act to require the Department of Health and Human Services (HHS) to carry out hepatitis B (HBV) and hepatitis C (HCV) virus infection surveillance, education, and testing programs. Requires HHS to establish a national system regarding HBV and HCV infections, with its goals being to: determine the prevalence of infections, increase the number of individuals tested and made aware of their status, develop and disseminate public information and education programs, improve the training of health professionals, and provide referrals for counseling and medical treatment and ensure the provision of follow-up services. Directs HHS to determine the populations that are considered at high risk for HBV or HCV infection. Requires HHS to develop benchmarks for activities conducted under the Action Plan for the Prevention, Care, & Treatment of Viral Hepatitis. Directs HHS to establish and support public-private partnerships that facilitate HBV and HCV surveillance, education, screening, testing, and linkage to care programs. Requires the Agency for Healthcare Research and Quality to convene the U.S. Preventive Services Task Force every three years to review its recommendation for HBV and HCV screening. Directs the Department of Veterans Affairs (VA) to provide certain veterans with an HBV and HCV risk assessment, and, as needed, an evaluation and information regarding their need for treatment, vaccination, or other therapy.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (5)
2017 · second_quarter · Health Issues
Pending health care legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; HR 1628 American Health Care Act and S. __ Better Care Reconciliation Act; HCV screening and linkage to care programs; H.R. 2430 and S. 934, FDA Reauthorization Act. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program; S.524 - Comprehensive Addiction and Recovery Act of 2016 - HCV testing provision in bill; S. 1287 - Viral Hepatitis Act of 2015. Prison population and Hepatitis C.
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Introduced in Senate
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: Not reported · Firm income: $10,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2017 · first_quarter · Health Issues
Pending health care legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV screening and linkage to care programs; H.R. 6 - 21st Century Cures Act. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. S. 3056 CREATES Act of 2016; S.524 - Comprehensive Addiction and Recovery Act of 2016 - HCV testing provision in bill; S. 1287 - Viral Hepatitis Act of 2015. Prison population and Hepatitis C.
Client expense: Not reported · Firm income: $14,500
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · first_quarter · Health Issues
H.R. 1101 - Viral Hepatitis Testing Act S. 1287 - Viral Hepatitis Testing Act Issues related to testing and treatment of Hepatitis Biosimilars FDA Reform 21st Century Cures 340B Program Issues related to patient access
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
2016 · fourth_quarter · Health Issues
H.R. 1101 - Viral Hepatitis Testing Act S. 1287 - Viral Hepatitis Testing Act Issues related to testing and treatment of Hepatitis Biosimilars FDA Reform 21st Century Cures 340B Program Issues related to patient access
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
2016 · fourth_quarter · Health Issues
Pending healthcare legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV screening and linkage to care programs; H.R. 6 - 21st Century Cures Act. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. S. 3056 - CREATES Act of 2016; S.524 - Comprehensive Addiction and Recovery Act of 2016 - HCV testing provision in bill; S.1287 - Viral Hepatitis Testing Act of 2015. Prison population and hepatitis C.The FOCUS program.
Client expense: $960,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), Veterans Affairs, Dept of (VA)
2016 · fourth_quarter · Health Issues
Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program. S.1287 - Viral Hepatitis Testing Act of 2015
Client expense: Not reported · Firm income: $70,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Health Issues
Pending healthcare legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV screening and linkage to care programs; H.R. 6 - 21st Century Cures Act. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. S. 3056 - CREATES Act of 2016; S.524 - Comprehensive Addiction and Recovery Act of 2016 - HCV testing provision in bill; S.1287 - Viral Hepatitis Testing Act of 2015. Prison population and hepatitis C.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · third_quarter · Health Issues
H.R. 1101 - Viral Hepatitis Testing Act S. 1287 - Viral Hepatitis Testing Act Issues related to testing and treatment of Hepatitis Biosimilars FDA Reform 21st Century Cures 340B Program Issues related to patient access
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
2016 · first_quarter · Health Issues
H.R. 6, 21st Century Cures Act S. 2700, FDA and NIH Workforce Authorities Modernization Act; H.R. 3381, Childhood Cancer STAR Act; Discussions to clarify or reform the 340B program; Biologics Price Competition and Innovation Act; H.R. 1101 & S. 1287, Viral Hepatitis Testing Act; Public Law 111-148, The Patient Protection and Affordable Care Act; H.R. 471 & S. 483, Ensuring Patient Access and Effective Drug Enforcement of 2015; H.R. 1725 & S. 480, National All Schedules Prescription Electronic Reporting Reauthorization of 2015; H.R. 2228 & S.122, Safe and Affordable Drugs from Canada Act of 2015; Proposals to address prescription drug abuse; Implementation of The Prescription Drug User Fee Act (PDUFA); Implementation of The Biosimilars User Fee Act (BsUFA); Public Law 113-54, Drug Quality & Security Act; H.R. 639 & S. 481, Improving Regulatory Transparency for New Medical Therapies; H.R. 2570 & S. 1396, Value-Based Insurance Design Seniors Copayment Reduction Act of 2015; H.R. 3677 Opioid Abuse Prevention and Treatment Act of 2015; S. 524, Comprehensive Addiction and Recovery Act of 2016;
Client expense: $2,610,000 · Firm income: Not reported
2016 · third_quarter · Health Issues
H.R. 6, 21st Century Cures Act; S. 2700, FDA and NIH Workforce Authorities Modernization Act; Discussions to clarify or reform the 340B program; Biologics Price Competition and Innovation Act; H.R. 1101 & S. 1287, Viral Hepatitis Testing Act; Public Law 111-148, The Patient Protection and Affordable Care Act; H.R. 2228 & S.122, Safe and Affordable Drugs from Canada Act of 2015; Proposals to address prescription drug abuse; Implementation/Reauthorization of The Prescription Drug User Fee Act (PDUFA); Implementation/Reauthorization of The Biosimilars User Fee Act (BsUFA); H.R. 639 & S. 481, Improving Regulatory Transparency for New Medical Therapies; H.R. 2570 & S. 1396, Value-Based Insurance Design Seniors Copayment Reduction Act of 2015; H.R. 3677 Opioid Abuse Prevention and Treatment Act of 2015; S. 524, Comprehensive Addiction and Recovery Act of 2016; H.R. 3012 & S. 2912, Trickett Wendler Right to Try Act of 2016; H.R. 6043 & S. 3335, Fair Accountability and Innovative Research Drug Pricing Act of 2016; H.R. 6174, Closing Loopholes for Orphan Drugs Act; S.3239, RACE for Children Act; Expanded Access (legislation not introduced); H.R. 4207, Medicare Fair Drug Pricing Act of 2015; Clinton's 1993 Health Security Act;
Client expense: $1,920,000 · Firm income: Not reported
2016 · third_quarter · Health Issues
Pending healthcare legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV screening and linkage to care programs; House Committee on Energy and Commerce 21st Century Cures initiative. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. S. 3056 - CREATES Act of 2016; S.524 - Comprehensive Addiction and Recovery Act of 2016 - HCV testing provision in bill; S.1287 - Viral Hepatitis Testing Act of 2015. Prison population and hepatitis C.
Client expense: $780,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Indian Health Service, Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), Veterans Affairs, Dept of (VA)
2016 · third_quarter · Health Issues
H.R. 1101 - Viral Hepatitis Testing Act S. 1287 - Viral Hepatitis Testing Act Issues related to testing and treatment of Hepatitis Biosimilars FDA Reform 21st Century Cures 340B Program Issues related to patient access
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
2016 · third_quarter · Health Issues
Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program. S.1287 - Viral Hepatitis Testing Act of 2015
Client expense: Not reported · Firm income: $70,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Health Issues
Pending healthcare legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV screening and linkage to care programs; House Committee on Energy and Commerce 21st Century Cures initiative. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. S. 3056 - CREATES Act of 2016; S.524 - Comprehensive Addiction and Recovery Act of 2016 - HCV testing provision in bill; S.1287 - Viral Hepatitis Testing Act of 2015. Prison population and hepatitis C.
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · second_quarter · Health Issues
H.R. 1101 - Viral Hepatitis Testing Act S. 1287 - Viral Hepatitis Testing Act Issues related to testing and treatment of Hepatitis Biosimilars FDA Reform 21st Century Cures 340B Program Issues related to patient access
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
2016 · first_quarter · Health Issues
H.R. 6, 21st Century Cures Act S. 2700, FDA and NIH Workforce Authorities Modernization Act; H.R. 3381, Childhood Cancer STAR Act; Discussions to clarify or reform the 340B program; Biologics Price Competition and Innovation Act; H.R. 1101 & S. 1287, Viral Hepatitis Testing Act; Public Law 111-148, The Patient Protection and Affordable Care Act; H.R. 471 & S. 483, Ensuring Patient Access and Effective Drug Enforcement of 2015; H.R. 1725 & S. 480, National All Schedules Prescription Electronic Reporting Reauthorization of 2015; H.R. 2228 & S.122, Safe and Affordable Drugs from Canada Act of 2015; Proposals to address prescription drug abuse; Implementation of The Prescription Drug User Fee Act (PDUFA); Implementation of The Biosimilars User Fee Act (BsUFA); Public Law 113-54, Drug Quality & Security Act; H.R. 639 & S. 481, Improving Regulatory Transparency for New Medical Therapies; H.R. 2570 & S. 1396, Value-Based Insurance Design Seniors Copayment Reduction Act of 2015; H.R. 3677 Opioid Abuse Prevention and Treatment Act of 2015; S. 524, Comprehensive Addiction and Recovery Act of 2016;
Client expense: $2,600,000 · Firm income: Not reported
2016 · first_quarter · Health Issues
H.R. 6, 21st Century Cures Act S. 2700, FDA and NIH Workforce Authorities Modernization Act; H.R. 3381, Childhood Cancer STAR Act; Discussions to clarify or reform the 340B program; Biologics Price Competition and Innovation Act; H.R. 1101 & S. 1287, Viral Hepatitis Testing Act; Public Law 111-148, The Patient Protection and Affordable Care Act; H.R. 471 & S. 483, Ensuring Patient Access and Effective Drug Enforcement of 2015; H.R. 1725 & S. 480, National All Schedules Prescription Electronic Reporting Reauthorization of 2015; H.R. 2228 & S.122, Safe and Affordable Drugs from Canada Act of 2015; Proposals to address prescription drug abuse; Implementation of The Prescription Drug User Fee Act (PDUFA); Implementation of The Biosimilars User Fee Act (BsUFA); Public Law 113-54, Drug Quality & Security Act; H.R. 639 & S. 481, Improving Regulatory Transparency for New Medical Therapies; H.R. 2570 & S. 1396, Value-Based Insurance Design Seniors Copayment Reduction Act of 2015; H.R. 3677 Opioid Abuse Prevention and Treatment Act of 2015; S. 524, Comprehensive Addiction and Recovery Act of 2016;
Client expense: $26,000,000 · Firm income: Not reported
2016 · second_quarter · Health Issues
Pending healthcare legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV screening and linkage to care programs; House Committee on Energy and Commerce 21st Century Cures initiative. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program; implementation of section 340B drug discount program. S. 3056 - CREATES Act of 2016; S.524 - Comprehensive Addiction and Recovery Act of 2016 - HCV testing provision in bill; S.1287 - Viral Hepatitis Testing Act of 2015. Prison population and hepatitis C.
Client expense: $760,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), Veterans Affairs, Dept of (VA)
2016 · second_quarter · Health Issues
Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program. S.1287 - Viral Hepatitis Testing Act of 2015
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Health Issues
Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program. S.1287 - Viral Hepatitis Testing Act of 2015
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · first_quarter · Health Issues
H.R. 1101 - Viral Hepatitis Testing Act S. 1287 - Viral Hepatitis Testing Act Issues related to testing and treatment of Hepatitis Biosimilars FDA Reform 21st Century Cures 340B Program Issues related to patient access
Client expense: Not reported · Firm income: $50,000
2016 · first_quarter · Health Issues
H.R. 6, 21st Century Cures Act S. 2700, FDA and NIH Workforce Authorities Modernization Act; H.R. 3381, Childhood Cancer STAR Act; Discussions to clarify or reform the 340B program; Biologics Price Competition and Innovation Act; H.R. 1101 & S. 1287, Viral Hepatitis Testing Act; Public Law 111-148, The Patient Protection and Affordable Care Act; H.R. 471 & S. 483, Ensuring Patient Access and Effective Drug Enforcement of 2015; H.R. 1725 & S. 480, National All Schedules Prescription Electronic Reporting Reauthorization of 2015; H.R. 2228 & S.122, Safe and Affordable Drugs from Canada Act of 2015; Proposals to address prescription drug abuse; Implementation of The Prescription Drug User Fee Act (PDUFA); Implementation of The Biosimilars User Fee Act (BsUFA); Public Law 113-54, Drug Quality & Security Act; H.R. 639 & S. 481, Improving Regulatory Transparency for New Medical Therapies; H.R. 2570 & S. 1396, Value-Based Insurance Design Seniors Copayment Reduction Act of 2015; H.R. 3677 Opioid Abuse Prevention and Treatment Act of 2015; S. 524, Comprehensive Addiction and Recovery Act of 2016;
Client expense: $2,570,000 · Firm income: Not reported
2016 · first_quarter · Health Issues
H.R. 6, 21st Century Cures Act S. 2700, FDA and NIH Workforce Authorities Modernization Act; H.R. 3381, Childhood Cancer STAR Act; Discussions to clarify or reform the 340B program; Biologics Price Competition and Innovation Act; H.R. 1101 & S. 1287, Viral Hepatitis Testing Act; Public Law 111-148, The Patient Protection and Affordable Care Act; H.R. 471 & S. 483, Ensuring Patient Access and Effective Drug Enforcement of 2015; H.R. 1725 & S. 480, National All Schedules Prescription Electronic Reporting Reauthorization of 2015; H.R. 2228 & S.122, Safe and Affordable Drugs from Canada Act of 2015; Proposals to address prescription drug abuse; Implementation of The Prescription Drug User Fee Act (PDUFA); Implementation of The Biosimilars User Fee Act (BsUFA); Public Law 113-54, Drug Quality & Security Act; H.R. 639 & S. 481, Improving Regulatory Transparency for New Medical Therapies; H.R. 2570 & S. 1396, Value-Based Insurance Design Seniors Copayment Reduction Act of 2015; H.R. 3677 Opioid Abuse Prevention and Treatment Act of 2015; S. 524, Comprehensive Addiction and Recovery Act of 2016;
Client expense: $2,630,000 · Firm income: Not reported
2016 · first_quarter · Health Issues
Pending healthcare legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV screening and linkage to care programs; House Committee on Energy and Commerce 21st Century Cures initiative. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program. S.1287 - Viral Hepatitis Testing Act of 2015. Prison population and hepatitis C.
Client expense: $980,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), Veterans Affairs, Dept of (VA)
2015 · fourth_quarter · Health Issues
Pending healthcare legislation and potential impact on the biopharmaceutical industry; Ryan White Care Act reauthorization; Hepatitis C policy; PEPFAR reauthorization; HIV/AIDS research, testing, and treatment; Affordable Care Act implementation; HCV screening and linkage to care programs; House Committee on Energy and Commerce 21st Century Cures initiative. Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program. S.1287 - Viral Hepatitis Testing Act of 2015.
Client expense: $890,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), Veterans Affairs, Dept of (VA)
2015 · fourth_quarter · Health Issues
Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program. S.1287 - Viral Hepatitis Testing Act of 2015
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · fourth_quarter · Health Issues
H.R. 1101 - Viral Hepatitis Testing Act S. 1287 - Viral Hepatitis Testing Act Biosimilars FDA Reform 21st Century Cures 340B Program Issues related to patient access
Client expense: Not reported · Firm income: $50,000
2015 · fourth_quarter · Health Issues
H.R. 6, 21st Century Cures Act; Discussions to clarify or reform the 340B program; Biologics Price Competition and Innovation Act; H.R. 1101 & S. 1287, Viral Hepatitis Testing Act; Public Law 111-148, The Patient Protection and Affordable Care Act; Public Law 111-152, The Health Care and Education Reconciliation Act; H.R. 2228 & S.122, Safe and Affordable Drugs from Canada Act of 2015; Proposals to address prescription drug abuse; Implementation of The Prescription Drug User Fee Act (PDUFA); Implementation of The Biosimilars User Fee Act (BsUFA); H.R. 2570 & S. 1396, Value-Based Insurance Design Seniors Copayment Reduction Act of 2015; H.R. 3677 Opioid Abuse Prevention and Treatment Act of 2015;
Client expense: $1,180,000 · Firm income: Not reported
2015 · third_quarter · Health Issues
Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program. S.1287 - Viral Hepatitis Testing Act of 2015
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · third_quarter · Health Issues
H.R. 1101 - Viral Hepatitis Testing Act S. 1287 - Viral Hepatitis Testing Act Biosimilars FDA Reform 21st Century Cures
Client expense: Not reported · Firm income: $50,000
2015 · third_quarter · Health Issues
H.R. 6, 21st Century Cures Act; Discussions to clarify or reform the 340B program; Biologics Price Competition and Innovation Act; H.R. 2031, TEST Act; H.R. 1101 & S. 1287, Viral Hepatitis Testing Act; Public Law 111-148, The Patient Protection and Affordable Care Act; Implementation of The Prescription Drug User Fee Act (PDUFA);
Client expense: $1,240,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2015 · second_quarter · Health Issues
H.R. 6, 21st Century Cures Act; Discussions to clarify or reform the 340B program; Biologics Price Competition and Innovation Act; H.R. 2031, TEST Act; H.R. 1101 & S. 1287, Viral Hepatitis Testing Act; Proposals to improve viral hepatitis screening and testing; Public Law 111-148, The Patient Protection and Affordable Care Act; Public Law 111-152, The Health Care and Education Reconciliation Act; Implementation of The Prescription Drug User Fee Act (PDUFA); H.R. 2570 & S. 1396, Value-Based Insurance Design Seniors Copayment Reduction Act of 2015; Proposals to address chronic care coordination; Discussions on international health policy including World Health Organization resolutions;
Client expense: $930,000 · Firm income: Not reported
2015 · second_quarter · Health Issues
H.R. 1101 - Viral Hepatitis Testing Act S. 1287 - Viral Hepatitis Testing Act Biosimilars FDA Reform 21st Century Cures
Client expense: Not reported · Firm income: $50,000
2015 · second_quarter · Health Issues
Funding for HCV and public health activities via appropriations. Pharmaceutical policy as it relates to payments under the 340B program. S.1287 - Viral Hepatitis Testing Act of 2015
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · second_quarter · Health Issues
H.R. 6, 21st Century Cures Act; Discussions to clarify or reform the 340B program; Biologics Price Competition and Innovation Act; H.R. 2031, TEST Act; H.R. 1101 & S. 1287, Viral Hepatitis Testing Act; Proposals to improve viral hepatitis screening and testing; Public Law 111-148, The Patient Protection and Affordable Care Act; Public Law 111-152, The Health Care and Education Reconciliation Act; Implementation of The Prescription Drug User Fee Act (PDUFA); H.R. 2570 & S. 1396, Value-Based Insurance Design Seniors Copayment Reduction Act of 2015; Proposals to address chronic care coordination; Discussions on international health policy including World Health Organization resolutions;
Client expense: $970,000 · Firm income: Not reported
| Democratic |
| NY |
| Martin Heinrich | Democratic | NM |
| Mazie K. Hirono | Democratic | HI |
| Michael F. Bennet | Democratic | CO |
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), Veterans Affairs, Dept of (VA)
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), Veterans Affairs, Dept of (VA)
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), Veterans Affairs, Dept of (VA)
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Veterans Affairs, Dept of (VA)
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), Veterans Affairs, Dept of (VA)
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), Veterans Affairs, Dept of (VA)
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)